Alternatively, the monomeric compound, tirzepatide (ZepboundTM), targets both GLP-1R and glucose-dependent insulinotropic polypeptide receptor (GIPR), and was recently reported to elicit 20.9% and 25.3% weight loss in humans with obesity over 72- [10] and 88-week trials [11]. This evidence concerns the gene GIPR and obesity disorder.